New One-Dose Havrix For Children In UK

2 June 1996

SmithKline Beecham has launched a new single-dose formulation of its hepatitis A vaccine Havrix in the UK. Havrix Junior Monodose is the first single-dose pediatric vaccine to be made available in the UK, notes the company. A single-dose adult version has been available for some time.

SB's first pediatric hepatitis A vaccine, Havrix Junior, requires a primary two-dose course and a booster. Children immunized with a single dose of Havrix Junior Monodose will be protected for at least one year, but will need a booster at between six and 12 months to achieve persistent immunity of up to 10 years.

The company notes that the single-dose format will help clinics achieve their vaccination targets more easily.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight